Overview

To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of rifampicin on the way the body handles darexaban and its metabolites (drug degradation products). The secondary objective of the study is to evaluate the safety and tolerability of a single dose of darexaban alone and when administered together with rifampicin.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Darexaban
Rifampin